Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) | DelveInsight

According to DelveInsight's analysis, the primary sclerosing cholangitis market is anticipated to grow during the forecast period (2025–2034), driven by the launch of emerging therapies such as LB-P8 (LISCure Biosciences), Volixibat (Mirum Pharmaceuticals), IQIRVO (Elafibranor) (Ipsen), Nebokitug (Chemomab Therapeutics), and others, and healthcare spending in the 7MM.

LAS VEGAS, Feb. 5, 2026 /PRNewswire/ -- DelveInsight's Primary Sclerosing Cholangitis Market Insights report includes a comprehensive understanding of current treatment practices, primary sclerosing cholangitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Primary Sclerosing Cholangitis Market Summary

• The total primary sclerosing cholangitis treatment market size is expected to grow positively by 2034 in the leading markets.
• The United States accounts for the largest market size of primary sclerosing cholangitis, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
• In 2024, the total diagnosed prevalent cases in the 7MM were found to be 90K.
• Leading primary sclerosing cholangitis companies, such as LISCure Biosciences, Mirum Pharmaceuticals, Ipsen, Chemomab Therapeutics, and others, are developing new primary sclerosing cholangitis treatment drugs that can be available in the primary sclerosing cholangitis market in the coming years. 
• The promising primary sclerosing cholangitis therapies in clinical trials include LB-P8, Volixibat, IQIRVO (Elafibranor), Nebokitug, and others.

Discover how large is the PSC market now and what will it be in 2034 @ https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Driving the Growth of the Primary Sclerosing Cholangitis Market 

• Rising PSC Prevalence: PSC incidence is increasing alongside related conditions like inflammatory bowel disease, liver failure, and bile duct cancer. This boosts demand for diagnostics and therapies, with prevalence estimates as high as 16.2 per 100,000 in high-incidence regions.
• Enhanced Diagnostic Capabilities: Advancements in non-invasive imaging and biomarker technologies (e.g., MRCP, ERCP, cholangiography, and emerging serological tests) are improving early detection.
• Emerging PSC Therapeutic Candidates in Development: Promising candidates such as LB-P8 (LISCure Biosciences), Volixibat (Mirum Pharmaceuticals), IQIRVO (Elafibranor) (Ipsen), Nebokitug (Chemomab Therapeutics), and others reflect growing efforts to target both the molecular and symptomatic aspects of the disease.

Primary Sclerosing Cholangitis Market Analysis

• The management of primary sclerosing cholangitis remains challenging due to the absence of an established curative therapy.
• Ursodeoxycholic acid (UDCA) has been widely studied as a potential treatment; however, clinical guidelines provide conflicting recommendations regarding its use.
• Multiple pharmacologic therapies, including prednisolone, budesonide, colchicine, penicillamine, azathioprine, tacrolimus, methotrexate, mycophenolate mofetil, and anti–tumor necrosis factor agents, have been evaluated without demonstrating proven clinical benefit in PSC.
• For patients with dominant biliary strictures, defined as narrowing of less than 1.5 mm in the common bile duct or less than 1.0 mm in the hepatic ducts, who present with pruritus or cholangitis, endoscopic retrograde cholangiopancreatography (ERCP) with balloon dilation is recommended to relieve symptoms.
• Surgical management options for PSC include biliary reconstructive procedures such as choledochoduodenostomy and choledochojejunostomy to improve bile drainage.
• The PSC market remains largely untapped due to the lack of approved disease-modifying therapies.
• Current treatment strategies are primarily symptomatic and have limited impact on disease progression, underscoring a substantial unmet medical need.
• Pharmaceutical development in PSC has been constrained by the disease's rarity, complex pathophysiology, and lack of validated biomarkers for clinical and regulatory advancement.
• Despite these challenges, the increasing prevalence of disease, orphan drug incentives, and high unmet demand create significant opportunities for innovation.
• Overall, PSC represents a low-competition, high-value niche where targeted investment and novel therapeutics could transform patient outcomes and unlock a largely unexplored market.

Primary Sclerosing Cholangitis Competitive Landscape

Some of the PSC therapies in the pipeline include LB-P8 (LISCure Biosciences), Volixibat (Mirum Pharmaceuticals), IQIRVO (Elafibranor) (Ipsen), Nebokitug (Chemomab Therapeutics), and others.

LISCure Biosciences' LB-P8 is an orally administered, once-daily live biotherapeutic consisting of a single microbial strain designed to modulate fibrosis and inflammation via the gut–liver axis. Its anti-fibrotic and anti-inflammatory activity has been demonstrated across multiple preclinical models, including primary sclerosing cholangitis (PSC), metabolic dysfunction–associated steatohepatitis (MASH), and inflammatory bowel disease (IBD).

Mirum Pharmaceuticals' Volixibat is an oral, minimally absorbed inhibitor of the ileal bile acid transporter (IBAT) that reduces bile acid levels by preventing their intestinal reabsorption, thereby lowering systemic and hepatic bile acid exposure. The compound is currently being evaluated in the Phase IIb VISTAS trial for PSC. In 2024, the study met its prespecified efficacy and safety criteria at a blinded interim analysis for dose selection, highlighting its encouraging clinical potential. No new safety signals were observed, with diarrhea as the most common mild-to-moderate adverse event.

Ipsen's Elafibranor is an oral agonist of peroxisome proliferator-activated receptors (PPAR) α and δ. Activation of these receptors reduces bile acid toxicity and improves cholestasis by regulating bile acid synthesis, detoxification, and transporter expression. In addition, activation of PPARα and PPARδ confers anti-inflammatory effects through multiple signaling pathways.

The anticipated launch of these emerging therapies are poised to transform the primary sclerosing cholangitis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the primary sclerosing cholangitis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about which emerging drugs will affect the PSC market @ Primary Sclerosing Cholangitis Drugs Market 

Recent Developments in the Primary Sclerosing Cholangitis Market

• In December 2025, Chemomab Therapeutics Ltd. reported that findings from its Phase 2 SPRING study evaluating nebokitug in patients with primary sclerosing cholangitis (PSC) have been published in the latest issue of the American Journal of Gastroenterology.
• In September 2025, Mirum Pharmaceuticals completed enrollment in the Phase IIb VISTAS trial evaluating volixibat, an oral IBAT inhibitor, for cholestatic pruritus in PSC. The study met its pre-specified efficacy and safety thresholds at the 2024 interim analysis, with topline results expected in Q2 2026.
• In April 2025, late-breaking data demonstrated that elafibranor demonstrated dose-dependent efficacy and a favorable safety profile over 12 weeks in patients with PSC, a rare liver disease with no approved treatments. 

What is Primary Sclerosing Cholangitis?

Primary sclerosing cholangitis (PSC) is a rare, chronic liver disease characterized by ongoing inflammation, fibrosis, and progressive narrowing of the bile ducts inside and outside the liver. This leads to impaired bile flow (cholestasis), causing bile to accumulate in the liver and gradually resulting in liver damage, cirrhosis, and eventually liver failure in some patients. PSC is strongly associated with inflammatory bowel disease, particularly ulcerative colitis, and often affects younger to middle-aged adults. The disease course is variable and unpredictable, with patients at increased risk of complications such as recurrent cholangitis, cholangiocarcinoma, and colorectal cancer. Currently, there is no curative medical therapy for PSC, and liver transplantation remains the only definitive treatment for advanced disease.

Primary Sclerosing Cholangitis Epidemiology Segmentation

The primary sclerosing cholangitis epidemiology section provides insights into the historical and current primary sclerosing cholangitis patient pool and forecasted trends for the leading markets. PSC affects men about twice as often as women. Although it can occur at any age, it most commonly develops in middle-aged adults.

The primary sclerosing cholangitis treatment market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

• Total Prevalent Cases of PSC
• Total Diagnosed Prevalent Cases of PSC
• Gender-specific Cases of PSC
• Comorbidity-specific Cases of PSC
• Treated Cases of PSC

Scope of the Primary Sclerosing Cholangitis Market Report

• Therapeutic Assessment: Primary Sclerosing Cholangitis current marketed and emerging therapies
• Primary Sclerosing Cholangitis Market Dynamics: Key Market Forecast Assumptions of Emerging Primary Sclerosing Cholangitis Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Primary Sclerosing Cholangitis Market Access and Reimbursement

Download the report to understand what factors are driving the PSC therapeutic market @ Primary Sclerosing Cholangitis Market Forecast

Table of Contents

Related Reports

Primary Sclerosing Cholangitis Clinical Trial Analysis

Primary Sclerosing Cholangitis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Primary Sclerosing Cholangitis companies, including Gilead Sciences, Immunic, Dr Falk Pharma, Pliant Therapeutics, CymaBay Therapeutics, SCOHIA PHARMA, Albireo Pharma, Sirnaomics, Morphic Therapeutic, and others.

Inflammatory Bowel Disease Market

Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IBD companies including Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, and others.

Ulcerative Colitis Market

Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ulcerative colitis companies including Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast, and others.

Crohn's Disease Market

Crohn's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn's disease companies including RedHill Biopharma, Merck, Teva Pharmaceutical, Pfizer, Agomab Therapeutics, Sanofi, Medibiofarma, Eli Lilly, NImmune, Avobis Bio, Abivax, Roche, Telavant, Mesoblast, Takeda, AstraZeneca, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

21%

more press release views with 

Request a Demo